Recent Updates — AVHHL

AVITA Medical reported third-quarter total revenue of $26.1 million, a 53% increase from the prior year and a 20% sequential rise, driven by strong RECELL adoption and growing Cohealyx sales. Gross margin expanded to 84.0%, while operating expenses remained flat at $24.6 million despite performance-based compensation increases. The company raised its full-year 2026 revenue guidance to the $92 million to $94 million range, up from the previous estimate of $86 million to $89 million, and reaffirmed expectations for cash flow breakeven in Q4. Additionally, AVITA Medical drew down an additional $10 million tranche under its credit facility with Perceptive Advisors LLC after achieving a trailing twelve-month revenue milestone of $85 million, strengthening its liquidity position.

On October 26, 2026, Perceptive Credit Holdings V, LP exercised its warrant to purchase up to 500,000 shares of AVITA Medical common stock on a cashless basis. The company withheld 112,284 shares to cover the exercise price and issued 387,716 new shares to Perceptive on October 28, 2026. This transaction was disclosed via filings with the Australian Securities Exchange on November 2, 2026. AVITA Medical develops medical devices for wound care.

AVITA Medical, Inc. held its 2026 Annual Meeting of Stockholders on June 3, 2026, where shareholders elected seven directors and ratified Grant Thornton LLP as the independent auditor. Stockholders approved increasing the non-executive director cash fee pool from $750,000 to $900,000 per annum, as well as various equity grants for directors. Additionally, the company received approval to issue warrants for up to 650,000 shares to Perceptive Credit Holdings V, LP and to issue equity securities up to an additional 10% of issued capital per ASX Listing Rule 7.1A.